Thioredoxin-1 suppresses systemic inflammatory responses against cigarette smoking

Antioxidants and Redox Signaling

Volumn 8, Issue 9-10, 2006, Pages 1891-1896

  Sato, Atsuyasu ^a   Hara, Tomijiro ^b   Nakamura, Hajime ^c   Kato, Noriko ^b,d   Hoshino, Yuma ^c   Kondo, Norihiko ^b   Mishima, Michiaki ^a   Yodoi, Junji ^b,c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d Redox Bioscience Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; THIOREDOXIN; THIOREDOXIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBONYLATION; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE MODEL; GENE OVEREXPRESSION; HEART; INFLAMMATION; LIVER; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SPLEEN;

ANIMALS; HUMANS; INFLAMMATION; LIVER; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEINS; SMOKING; SPLEEN; THIOREDOXIN; TUMOR NECROSIS FACTOR-ALPHA;

MUS MUSCULUS;

EID: 33750904409     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2006.8.1891     Document Type: Article

References (36)

1. Bloom B R and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82, 1966.
2. Bostrom L, Linder L E, and Bergstrom J. Clinical expression of TNF-alpha in smoking-associated periodontal disease. J Clin Periodontol 25: 767-773, 1998.
3. Broekhuizen R, Grimble RF, Howell WM, Shale DJ, Creutzberg EC, Wouters EF, and Schols AM. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta-511 single nucleotide polymorphism. Am J Clin Nutr 82: 1059-1064, 2005.
4. Calandra T, Bernhagen J, Mitchell RA, and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902, 1994.
5. Calandra T and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800, 2003.
6. Di Francia M, Barbier D, Mege JL, and Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150: 1453-1455, 1994.
7. Hattori I, Takagi Y, Nakamura H, Nozaki K, Bai J, Kondo N, Sugino T, Nishimura M, Hashimoto N, and Yodoi J. Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid Redox Signal 6: 81-87, 2004.
8. Higuchi MA, Sagartz J, Shreve WK, and Ayres PH. Comparative subchronic inhalation study of smoke from the 1R4F and 2R4F reference cigarettes. Inhal Toxicol 16: 1-20, 2004.
9. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94: 3633-3638, 1997.
10. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
11. Hirota K, Nakamura H, Arai T, Ishii H, Bai J, Itoh T, Fukuda K, and Yodoi J. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun 275: 825-830, 2000.
12. Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H, and Yodoi J. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 168: 1075-1083, 2003.
13. Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, and Yamakado M. Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 28: 27-34, 2005.
14. Kaimul Ahsan M, Nakamura H, Tanito M, Yamada K, Utsumi H, and Yodoi J. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med 39: 1549-1559, 2005.
15. Kasuno K, Nakamura H, Ono T, Muso E, and Yodoi J. Protective roles of thioredoxin, a redox-regulating protein, in renal ischemia/reperfusion injury. Kidney Int 64: 1273-1782, 2003.
16. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Juttner S, Brunner H, and Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 280: 85-102, 1998.
17. Kondo N, Ishii Y, Son A, Sakakura-Nishiyama J, Kwon YW, Tanito M, Nishinaka Y, Matsuo Y, Nakayama T, Taniguchi M, and Yodoi J. Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins. Immunol Lett 92: 143-147, 2004.
18. Lan HY, Yang N, Metz C, Mu W, Song Q, Nikolic-Paterson DJ, Bacher M, Bucala R, and Atkins RC. TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med 3: 136-144, 1997.
19. Liu W, Nakamura H, Shioji K, Tanito M, Oka SI, Ahsan MK, Son A, Ishii Y, Kishimoto C, and Yodoi J. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 110: 1276-1283, 2004.
20. Miwa K, Kishimoto C, Nakamura H, Makita T, Ishii K, Okuda N, Yodoi J, and Sasayama S. Serum thioredoxin and alpha-tocopherol concentrations in patients with major risk factors. Circ J 69: 291-294, 2005.
21. Mizia-Stec K, Zahorska-Markiewicz B, and Gasior Z. Cigarette smoking and inflammatory indices in coronary artery disease. Int J Cardiol 93: 169-174, 2004.
22. Nakamura H, Tamura S, Watanabe I, Iwasaki T, and Yodoi J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol Lett 82: 165-170, 2002.
23. Okuyama H, Nakamura H, Shimahara Y, Uyama N, Kwon YW, Kawada N, Yamaoka Y, and Yodoi J. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol 42: 117-123, 2005.
24. Ouyang Y, Virasch N, Hao P, Aubrey MT, Mukerjee N, Bierer BE, and Freed BM. Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts. J Allergy Clin Immunol 106: 280-287, 2000.
25. Pauwels RA, Buist AS, Ma P, Jenkins CR, and Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46: 798-825, 2001.
26. Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E, and Patakas D. Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med 96: 594-598, 2002.
27. Potolicchio I, Santambrogio L, and Strominger JL. Molecular interaction and enzymatic activity of macrophage migration inhibitory factor with immunorelevant peptides. J Biol Chem 278: 30889-30895, 2003.
28. Rahman I and MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 16: 534-554, 2000.
29. Rahman I and MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 53: 601-612, 1998.
30. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, and Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106: 1403-1409, 2002.
31. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBOJ 8: 757-764, 1989.
32. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, and Tomoike H. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1179-1184, 2000.
33. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, and Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 96: 4131-4136, 1999.
34. Tanito M, Kwon YW, Kondo N, Bai J, Masutani H, Nakamura H, Fujii J, Ohira A, and Yodoi J. Cytoprotective effects of geranylgeranylacetone against retinal photooxidative damage. J Neurosci 25: 2396-2404, 2005.
35. Yan F, Williams S, Griffin GD, Jagannathan R, Plunkett SE, Shafer KH, and Vo-Dinh T. Near-real-time determination of hydrogen peroxide generated from cigarette smoke. J Environ Monit 7: 681-687, 2005.
36. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, and Targher G. Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab 86: 3805-3808, 2001.